Inotiv, Inc. (NOTV) Company Overview

What does Inotiv do?

Inotiv, Inc. is a life-sciences contract research organization that supports drug discovery and nonclinical development while also supplying research models, diets, bedding, breeding, colony-management, and related services. The company historically traded under the ticker NOTV on the Nasdaq Capital Market, but its current corporate story is dominated by the voluntary Chapter 11 cases filed on June 3, 2026 and the subsequent suspension and delisting process. The operating platform remains built around two reportable segments: Discovery and Safety Assessment, or DSA, and Research Models and Services, or RMS. The latest fiscal 2026 second-quarter Form 10-Q describes those segments and the company’s continuing role in nonclinical research.

Which customers and research needs does it serve?

The customer base spans pharmaceutical and biotechnology companies, medical-device developers, universities, government research institutions, and other life-science organizations. DSA work includes discovery and translational sciences, toxicology, pathology, bioanalysis, surgical services, and regulated or nonregulated safety studies. RMS sells purpose-bred models, genetically engineered models, diets, bedding, enrichment, and specialized services such as breeding and colony care. In practical terms, Inotiv sits upstream of clinical trials: it helps clients select, test, and characterize drug candidates before or around investigational-new-drug submissions. Its official company website presents this integrated discovery-to-development proposition.

How does Inotiv make money?

Inotiv earns both service and product revenue. DSA is primarily a project-based service business. Contracts may be fixed-fee, milestone-based, or recognized over time as laboratory work is performed and direct costs are incurred. The economics depend on study volume, facility utilization, scientific labor, project mix, pricing, and the ability to schedule work efficiently. RMS combines product sales with recurring or semi-recurring services. Research-model sales are recognized when control transfers, while contract breeding and client-owned colony care are generally billed using per-diem arrangements. This creates a mixed model: some revenue is tied to discrete studies, while some is connected to ongoing care, breeding, and supply relationships.

Which revenue stream is largest?

For fiscal 2025, product revenue was $280.2 million and service revenue was $232.9 million, producing total revenue of $513.0 million. RMS generated $325.1 million, or about 63.4% of the annual total, while DSA generated $187.9 million, or about 36.6%. The annual mix therefore remained weighted toward research models and related products, even though DSA is strategically important because it connects models with higher-value scientific services. The fiscal 2025 Form 10-K provides the underlying segment and revenue-recognition detail.

Why does the integrated model matter?

The strategic logic is that a client can source models, diets, study design, laboratory execution, pathology, and analysis from one provider. Integration can reduce handoffs and improve scheduling, but it also increases operating complexity. Animal-breeding assets, specialized laboratories, scientific staffing, regulatory requirements, and customer-specific protocols create a large fixed-cost base. When volumes fall, especially in RMS, the company cannot remove costs as quickly as revenue declines. That operating leverage became visible in fiscal Q2 2026, when RMS revenue fell 10.7% year over year and segment operating performance swung sharply lower.

What did Inotiv’s latest reported period show?

The quarter ended March 31, 2026 showed a widening divergence between DSA and RMS. Consolidated revenue declined 5.4% to $117.7 million from $124.3 million a year earlier. DSA revenue increased 3.9% to $47.1 million, supported by safety-assessment activity, new business at the Rockville facility, and analytical and surgical services. RMS revenue decreased 10.7% to $70.6 million. Consolidated net loss expanded to $32.5 million, equal to 27.6% of revenue, from $14.9 million, or 12.0% of revenue, in the prior-year quarter.

What changed over the first six months?

For the six months ended March 31, 2026, revenue was $238.5 million, down 2.3% from $244.2 million. DSA revenue increased 7.8% to $95.0 million, while RMS revenue fell 8.0% to $143.5 million. DSA segment operating income improved to $14.3 million before segment depreciation and amortization presentation effects, while RMS recorded a segment operating loss of $5.5 million on the comparable management basis. Consolidated net loss for the six-month period reached $60.8 million, or 25.5% of revenue. The core signal is not simply slower growth; it is that the larger RMS segment was losing volume and profitability at the same time corporate costs and financing burdens remained high.

How did Inotiv reach its current strategic position?

Inotiv’s present scale was built through a long sequence of expansion and acquisitions. The company began as Bioanalytical Systems, a provider of scientific instruments and research services. It later broadened into a more comprehensive contract-research platform, adopted the Inotiv identity, and acquired multiple laboratory and research-model businesses. The decisive transaction was the 2021 acquisition of Envigo, which made RMS the largest segment and substantially increased debt, physical assets, animal-care obligations, and integration complexity. The company’s official history page highlights the BASi roots, the 2018 combination with Seventh Wave, and the Envigo acquisition.

1. 1974
   Bioanalytical Systems was founded, establishing the company’s laboratory-instrument and research-services base.
2. 2018
   The merger with Seventh Wave expanded nonclinical services and helped form the modern Inotiv platform.
3. 2019–2020
   The company rebranded around Inotiv and accelerated acquisition-led expansion in discovery and safety assessment.
4. 2021
   The Envigo acquisition added global research-model operations and transformed segment mix, scale, leverage, and regulatory exposure.
5. 2022–2024
   Integration, site optimization, animal-welfare remediation, legal matters, and financing amendments became central management tasks.
6. 2025
   Revenue improved modestly and RMS returned to reported segment profit, but cash flow remained negative and debt stayed above $400 million.
7. 2026
   Liquidity stress, covenant pressure, missed obligations, and a prepackaged Chapter 11 process shifted the focus from growth to balance-sheet restructuring.

What did the Envigo transaction change?

Envigo created the integrated model that still defines Inotiv, but it also introduced the strategic tension that defines the analysis. The company gained a broader customer proposition and a larger installed operating footprint, yet the acquired model-breeding network brought fixed costs, inventory intensity, animal-welfare scrutiny, regulatory risk, and debt. In a healthy demand environment, that infrastructure can support recurring relationships and cross-selling. In a weak environment, it can absorb cash and produce large losses. The acquisition therefore created both the principal strategic advantage and the principal financial vulnerability.

What gives Inotiv a competitive advantage?

Inotiv’s strongest potential advantage is breadth. Few providers combine research-model supply, diets and bedding, colony-management capabilities, discovery services, safety assessment, pathology, bioanalysis, surgical expertise, and regulatory-grade work in one organization. This can reduce vendor coordination for clients and create cross-selling opportunities. Specialized facilities, validated processes, scientific personnel, accreditations, model libraries, and long-standing client relationships also create barriers to entry. The company’s accreditations and certifications page illustrates the operating standards required across its network.

How durable is that moat?

The moat is real but conditional. Switching costs can be meaningful once a study is underway, because protocols, models, data, and timelines are specific. However, large pharmaceutical companies and biotechnology clients often use multiple CROs and can rebid projects. Research-model customers can also adjust demand quickly when funding slows or pipelines change. The company disclosed that one RMS customer represented 16.6% of fiscal 2025 revenue, showing that concentration can outweigh diversification. Scientific reputation and quality matter, but a financially constrained provider may struggle to retain employees, fund facilities, maintain model availability, or reassure customers. Inotov’s competitive resources therefore cannot be separated from its balance sheet.

Who are Inotiv’s main competitors?

Inotiv competes in fragmented but sophisticated markets. In DSA, major competitors include Charles River Laboratories, Labcorp’s former drug-development operations now operating as Fortrea in selected areas, WuXi AppTec, Pharmaron, and specialized regional CROs. In RMS, Charles River is again a major competitor, alongside Taconic Biosciences, The Jackson Laboratory, and other model breeders and service providers. Competition is based on scientific quality, regulatory record, capacity, model availability, turnaround time, geography, pricing, customer service, and the ability to execute complex programs.

Where is Inotiv most differentiated?

The differentiation is strongest where a customer values coordinated access to a specific model and the related scientific services. A client may need a specialized animal model, custom breeding, surgical preparation, toxicology, pathology, and bioanalysis in a connected workflow. Inotiv can offer that breadth. Yet procurement teams can still separate those services among vendors, and the company’s bankruptcy process may cause some customers to diversify suppliers. The competitive question is therefore not whether the platform is technically capable; it is whether Inotiv can preserve customer confidence and operating continuity while its capital structure is reset.

How financially strong was Inotiv before Chapter 11?

The prepetition balance sheet was highly leveraged and cash-constrained. At March 31, 2026, cash and cash equivalents were $15.2 million, down from $21.7 million at September 30, 2025. Total debt before unamortized issuance costs was $416.3 million, and net debt was $410.4 million. The company had $13.0 million drawn on its $15.0 million revolving facility and stated that existing liquidity and internally generated cash would not be sufficient for the next twelve months absent a transaction that improved liquidity and reduced debt. That disclosure was a direct going-concern warning, not a routine risk statement.

What did annual cash flow reveal?

Fiscal 2025 revenue increased 4.5% to $513.0 million from $490.7 million, and reported operating loss improved to $30.9 million from $86.4 million. Even so, net loss was $68.6 million. Net cash used in operating activities was $10.5 million, and capital expenditures were $16.6 million, implying an approximate free-cash-flow deficit of $27.1 million before financing. The company raised equity and relied on financing flows to keep cash roughly flat. This is the central financial lesson: better reported operating results did not translate into self-funded liquidity.

What do ownership and governance mean after the restructuring filing?

Before Chapter 11, Inotiv had a single class of common shares with dispersed public ownership and meaningful but noncontrolling insider stakes. As of January 16, 2026, 34.4 million common shares were outstanding. Chief Executive Officer Robert Leasure beneficially owned about 1.64 million shares, or 4.7%; Chief Strategy Officer John Sagartz owned about 696,791 shares, or 2.0%; and current directors and executive officers as a group owned about 3.67 million shares, or 10.7%. These figures were disclosed in the company’s 2025 Form 10-K/A governance amendment.

Why does creditor control now matter more than share ownership?

The restructuring support agreement fundamentally changed the governance lens. The plan contemplated cancellation of existing equity without a distribution to common shareholders, while consenting first-lien lenders, second-lien noteholders, and convertible noteholders supported a prepackaged reorganization. The company expected to emerge as a private company. In that setting, the most economically important stakeholders are no longer public shareholders but creditors providing restructuring support, debtor-in-possession financing, and expected exit financing. The June 2026 restructuring Form 8-K describes the plan, creditor support, and a $65.4 million DIP facility.

Which KPIs matter most for Inotiv?

The most informative operating metrics are DSA book-to-bill, DSA backlog, segment revenue, segment operating income, model-product demand, customer concentration, working-capital movement, operating cash flow, and liquidity. Book-to-bill compares new DSA awards with recognized revenue; a ratio above 1.0x indicates that awards exceeded revenue for the period. Backlog shows contracted work not yet recognized, although timing, cancellations, and study changes can affect conversion. At March 31, 2026, DSA backlog was $151.8 million, up from $138.2 million at September 30, 2025 and $130.8 million a year earlier. That was a positive demand signal even as consolidated finances deteriorated.

How should a researcher connect these metrics?

The sequence matters. Bookings create backlog; backlog converts into revenue; revenue must cover direct costs, facility overhead, corporate expense, interest, and capital spending; and the resulting cash flow must fund operations. Inotiv’s recent problem was that positive DSA bookings did not offset RMS weakness, corporate costs, debt service, and capital needs. A student using a value-chain or resource-based framework should therefore avoid treating backlog as a stand-alone strength. It is valuable only when the company has the people, facilities, customer confidence, and financing to execute the work profitably.

What risks could change Inotiv’s outlook?

The largest risk is execution of the Chapter 11 plan. Court approval, milestone compliance, DIP availability, vendor support, customer retention, employee retention, and emergence financing all matter. The company stated that it expected to emerge within 50 days as a private company, but restructuring agreements can be amended, delayed, challenged, or terminated. Nasdaq suspended trading on June 11, 2026, and the company did not appeal the delisting decision. The delisting Form 8-K also cautioned that the plan contemplated cancellation of existing common equity without distribution. The official delisting and DIP financing filing is therefore essential to any current analysis.

What operating and regulatory risks remain?

Even after financial restructuring, the business faces customer concentration, project cancellations, biotechnology funding cycles, research-model demand variability, labor shortages, animal-welfare obligations, transportation and supply-chain risks, cybersecurity exposure, facility disruptions, and regulatory scrutiny. Inotiv also has obligations connected with prior legal and regulatory resolutions. At March 31, 2026, it reported $13.1 million of liabilities associated with a resolution and plea agreement, with additional payments expected through June 2028 and interest accruing at 4.18%. The company’s animal-welfare commitments, described in its official animal-welfare statement, are strategically important because compliance failures can directly affect licenses, customer trust, costs, and reputation.

Why does Inotiv matter for valuation?

A conventional equity DCF is not the right starting point while legacy equity is expected to be cancelled. The valuation focus shifts to enterprise value, normalized operating cash flow, post-emergence debt, exit financing, restructuring claims, and the earning power of the reorganized private company. Analysts would need to estimate sustainable DSA growth, RMS stabilization, segment margins, corporate costs, maintenance capital expenditure, working-capital needs, and the cost of retaining regulatory-grade infrastructure. The proposed exit term loan facility could be as large as $150 million, inclusive of paid-in-kind interest, fees, original issue discount, and premiums, so the reorganized company may still carry meaningful leverage.

What would improve the post-emergence economics?

The most constructive scenario would combine DSA backlog conversion, renewed RMS product demand, better facility utilization, lower corporate expense, less cash interest, disciplined capital spending, and stable customer relationships. The negative scenario would involve customer migration, delayed studies, continued RMS weakness, high postpetition professional fees, or insufficient margin improvement. Because the company historically generated large depreciation and amortization charges, EBITDA can look better than net income, but cash flow must still cover maintenance spending, working capital, leases, and financing costs. For this reason, free cash flow after normalized capital expenditures is more informative than adjusted EBITDA alone.

What is the key takeaway from Inotiv analysis?